KDR and hemangioblastoma: Another clinical trial involving 6 VHL patients with hemangioblastomas investigated dovitinib, a tyrosine kinase inhibitor that targets FGFR, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).